Drug Profile
Bempegaldesleukin - Bristol Myers Squibb/Nektar Therapeutics
Alternative Names: BEMPEG; Bempegaldesleukinum; BMS-986321; NKTR-214; ONO-7911Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
- Developer BioXcel Therapeutics; Bristol-Myers Squibb; Merck & Co; Nektar Therapeutics; Nykode Therapeutics; Ono Pharmaceutical; SFJ Pharmaceuticals; Takeda; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Antivirals; Immunotherapies; Interleukins; Polyethylene glycols; Recombinant proteins
- Mechanism of Action CD8 positive T lymphocyte stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Cancer; Colorectal cancer; COVID 2019 infections; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Squamous cell cancer
Most Recent Events
- 18 Jan 2024 Nektar Therapeutics and Bristol-Myers Squibb completes the phase I/II PIVOT IO 011 trial in Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic desease) in USA, Canada, Germany, Argentina, Brazil, France, Germany, Mexico and Russia (IV) (NCT04540705)
- 31 Dec 2023 Discontinued - Phase-I for COVID-2019 infections (Combination therapy) in USA (IV)
- 31 Dec 2023 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Canada (IV)